BACKGROUND: Previous studies have suggested that women with cardiovascular disease may receive less aggressive care than men. Using a large cardiology database from a tertiary referral center, we sought to determine if treatment differences still persist in the current era. METHODS: We analyzed data on 2462 patients who were referred for secondary prevention to the Preventive Cardiology Clinic at The Cleveland Clinic Foundation between 1997 and 2004. The primary objective was to evaluate use of effective secondary preventive therapies, by gender, as outlined in the ACC/AHA guidelines, such as antiplatelet therapy, beta-blockers, statins, and angiotensin-converting enzyme (ACE) inhibitors. Multivariate logistic regression analysis was performed to assess the independent effect of gender on all cause mortality. RESULTS: Women were older (62.2 +/- 11.1 vs. 59.4 +/- 11.0, p < 0.001) and more likely to be hypertensive (68.1% vs. 56.1%, p < 0.001) than men. Overall, women were more likely than men to have higher baseline C-reactive protein (CRP) (6.14 +/- 13.4 vs. 4.9 +/- 10.7, p < 0.001), low-density lipoprotein cholesterol (LDL-C) (135 +/- 66 vs. 116 +/- 46, p < 0.001), high-density lipoprotein cholesterol (HDL-C) (52 +/- 17 vs. 41 +/- 11, p < 0.001), and total cholesterol (238 +/- 98 vs. 202 +/- 65, p < 0.001). Women were less likely to be on antiplatelet therapy (76.6 % vs. 85.0%, p < 0.001) and statins or any lipid-lowering therapy (62.6% vs. 67.1%, p = 0.04) compared with men on presentation. CONCLUSIONS: Even in the current era, women with established cardiovascular disease continue to receive less aggressive care than men. They are less likely to be on aspirin and statin therapy. More aggressive efforts should be made to treat both men and women with standard secondary preventive efforts.
BACKGROUND: Previous studies have suggested that women with cardiovascular disease may receive less aggressive care than men. Using a large cardiology database from a tertiary referral center, we sought to determine if treatment differences still persist in the current era. METHODS: We analyzed data on 2462 patients who were referred for secondary prevention to the Preventive Cardiology Clinic at The Cleveland Clinic Foundation between 1997 and 2004. The primary objective was to evaluate use of effective secondary preventive therapies, by gender, as outlined in the ACC/AHA guidelines, such as antiplatelet therapy, beta-blockers, statins, and angiotensin-converting enzyme (ACE) inhibitors. Multivariate logistic regression analysis was performed to assess the independent effect of gender on all cause mortality. RESULTS:Women were older (62.2 +/- 11.1 vs. 59.4 +/- 11.0, p < 0.001) and more likely to be hypertensive (68.1% vs. 56.1%, p < 0.001) than men. Overall, women were more likely than men to have higher baseline C-reactive protein (CRP) (6.14 +/- 13.4 vs. 4.9 +/- 10.7, p < 0.001), low-density lipoprotein cholesterol (LDL-C) (135 +/- 66 vs. 116 +/- 46, p < 0.001), high-density lipoprotein cholesterol (HDL-C) (52 +/- 17 vs. 41 +/- 11, p < 0.001), and total cholesterol (238 +/- 98 vs. 202 +/- 65, p < 0.001). Women were less likely to be on antiplatelet therapy (76.6 % vs. 85.0%, p < 0.001) and statins or any lipid-lowering therapy (62.6% vs. 67.1%, p = 0.04) compared with men on presentation. CONCLUSIONS: Even in the current era, women with established cardiovascular disease continue to receive less aggressive care than men. They are less likely to be on aspirin and statin therapy. More aggressive efforts should be made to treat both men and women with standard secondary preventive efforts.
Authors: E Lonn; S Yusuf; V Dzavik; C Doris; Q Yi; S Smith; A Moore-Cox; J Bosch; W Riley; K Teo Journal: Circulation Date: 2001-02-20 Impact factor: 29.690
Authors: William A Ghali; Peter D Faris; P Diane Galbraith; Colleen M Norris; Michael J Curtis; L Duncan Saunders; Vladimir Dzavik; L Brent Mitchell; Merril L Knudtson Journal: Ann Intern Med Date: 2002-05-21 Impact factor: 25.391
Authors: J G Canto; J J Allison; C I Kiefe; C Fincher; R Farmer; P Sekar; S Person; N W Weissman Journal: N Engl J Med Date: 2000-04-13 Impact factor: 91.245
Authors: Saif S Rathore; Yongfei Wang; Martha J Radford; Diana L Ordin; Harlan M Krumholz Journal: Ann Intern Med Date: 2002-09-17 Impact factor: 25.391
Authors: Linda S Kahn; Chester H Fox; Adefunke Olawaiye; Timothy J Servoss; Elizabeth McLean-Plunkett Journal: J Natl Med Assoc Date: 2007-04 Impact factor: 1.798
Authors: Min Zhao; Mark Woodward; Ilonca Vaartjes; Elizabeth R C Millett; Kerstin Klipstein-Grobusch; Karice Hyun; Cheryl Carcel; Sanne A E Peters Journal: J Am Heart Assoc Date: 2020-05-20 Impact factor: 5.501
Authors: Desirée Loikas; Björn Wettermark; Mia von Euler; Ulf Bergman; Karin Schenck-Gustafsson Journal: BMJ Open Date: 2013-05-03 Impact factor: 2.692